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OBJECTIVES The purpose of the study was to assess the mechanism responsible for increased stroke risk
in patients with atrial septal aneurysm (SA) and patent foramen ovale (PFO), and to
determine the efficacy of medical therapy for preventing stroke recurrence or death.
BACKGROUND Atrial septal aneurysm and PFO are associated with stroke. However, the mechanism for this
association is undefined, and the efficacy of medical therapy has not been investigated in a
randomized fashion.
METHODS The Patent foramen ovale In Cryptogenic Stroke Study (PICSS) evaluated transesophageal
echocardiography findings in patients enrolled in the Warfarin-Aspirin Recurrent Stroke
Study, a randomized double-blind trial to evaluate the efficacy of warfarin compared with
aspirin.
RESULTS Large PFO and prominent eustachian valve (EV) or right atrial (RA) filamentous strands
were found more frequently in patients with SA compared with those without SA (37.7% vs.
10.9%, p  0.001 and 59.4% vs. 43.1%, p  0.02). Patients with SA and PFO had no
significant difference in time to recurrent stroke or death compared with those having neither
(hazard ratio [HR] 1.08, 95% confidence interval [CI] 0.49 to 2.38, p 0.84; two-year event
rates 15.9% vs. 14.5%). Patients with SA, PFO, and RA anatomy predisposing to paradoxical
embolization also had no difference compared with those without these findings (HR 1.22,
95% CI 0.43 to 3.47, p  0.71; two-year event rates 18.2% vs. 14.2%). There was no
significant difference in time to recurrent stroke or death between the patients treated
with warfarin or aspirin (HR 1.00, 95% CI 0.22 to 4.47, p  1.0; two-year event rates
16.0% vs. 15.8%).
CONCLUSIONS Atrial septal aneurysm is associated with the presence of large PFO and prominent EV or RA
filamentous strands. On medical therapy, patients with SA and PFO did not experience
increased risk of adverse events, and there was no difference between treatment results for
warfarin and for aspirin. (J Am Coll Cardiol 2003;42:1066–72) © 2003 by the American
College of Cardiology Foundation
Atrial septal aneurysm (SA) and patent foramen ovale
(PFO) have been associated, separately, with stroke, and a
combination of SA and PFO has been shown to confer an
especially high risk (1–6). However, the mechanism for this
finding has not been clarified. Previously, it has been shown
that large PFOs are more often found in cryptogenic stroke
See page 1073
patients (7,8). Therefore, we sought to investigate the
characteristics of PFO found in stroke patients with SA.
The eustachian valve (EV) is a membrane-like structure in
the right atrium, a remnant of right valve of sinus venosus
that directs blood flow from the inferior vena cava (IVC) to
the fossa ovalis area in the fetal period (9). Prominence of
EV in adult life is reported to cause a significant right-to-
left shunt in the presence of interatrial communication by
altering the blood flow pattern (10,11). Filamentous strands
in right atrium which can span EV with atrial wall are also
a remnant of right valve of sinus venosus (12,13). When an
extensive network of strands is present, it is known as Chiari
network, which has been associated with paradoxical em-
bolization presumably by directing IVC flow towards the
fossa ovalis area (14,15). Given these findings, we hypoth-
esized that SA is associated with large PFO and that
prominent EV or right atrial (RA) filamentous strands are
more frequently found in patients with SA. The combina-
tion of a large PFO and a structure in right atrium diverting
IVC flow toward the PFO would likely lead to an increased
chance of paradoxical embolization.
A recent report indicates a significantly increased recur-
rent stroke risk in patients with SA and PFO, compared
with those having neither (16). We have recently reported
that on medical therapy the presence of SA in the overall
group of stroke patients with PFO did not increase the
adverse event rate beyond that seen with PFO alone (17).
However, this group was not compared with the patients
with neither SA nor PFO, and cryptogenic stroke patients
were not analyzed separately. Furthermore, the effect of RA
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anatomical variation on the adverse event rates in patients
with SA and PFO was not investigated. There is an
increasing use of percutaneous or surgical PFO closure to
potentially prevent paradoxical embolic events (18–21). In
order to define their proper role, it is necessary to rigorously
assess the risk of adverse events in conventionally medically
treated patients with PFO, particularly in a perceived
high-risk group, such as those with SA, PFO, and RA
anatomy predisposing to paradoxical embolization. There-
fore, in the current study, we investigated whether the
presence of SA and PFO, with or without RA anatomical
variation, alters the event rates when compared with the
patients without these findings.
METHODS
Patient recruitment. The Patent foramen ovale In Cryp-
togenic Stroke Study (PICSS) was a 42-center study that
tested the efficacy of medical therapy for stroke risk factors
identified by transesophageal echocardiography (TEE) (17).
Patients were drawn from the Warfarin-Aspirin Recurrent
Stroke Study (WARSS), a double-blind study to assess the
efficacy of warfarin compared with aspirin for prevention of
recurrent stroke or death in ischemic stroke patients (22).
Patient recruitment started in June 1993 and ended in June
1998. The PICSS patients consisted of WARSS patients
undergoing TEE for any clinical purpose, as well as
WARSS patients with cryptogenic stroke subtype who were
solicited to undergo TEE for PICSS entry (17). Clinical
data were collected by the Data Management Center in the
Stroke Unit of the Columbia-Presbyterian Medical Center.
All protocols for WARSS and PICSS were approved by the
institutional review board at each participating center, and
informed consent was obtained from each participant.
Eligibility. Patients age 30 to 85 years were eligible.
Eligible patients experienced ischemic stroke within the
previous 30 days and rated 3 on the Glasgow Outcome
Scale (representing severe disability, moderate disability, no
or minimal disability) (23). Ineligible patients had baseline
international normalized ratio (INR) above the normal
range (1.4), stroke related to a procedure, stroke attribut-
able to a cardioembolic source, or planned to undergo
surgery for high-grade carotid stenosis. Patients with a
contraindication to TEE were not considered for PICSS
entry.
Stroke subtyping. All baseline strokes were subtyped by a
local neurology principal investigator based on a predefined
criteria modeled after the National Institute of Neurological
Disorders and Stroke-Stroke Data Bank and Trial of
Organon in Acute Stroke Therapy (24). These subtypes
were: lacunar, large vessel, cryptogenic, other determined
cause, and conflicting mechanisms. Cryptogenic stroke
typically has no definite source despite a thorough diagnos-
tic evaluation (25).
Medications and blinding. Medications used were aspirin
325 mg tablets taken once daily, and warfarin in 2 mg scored
tablets taken once daily, adjusted to achieve and maintain
INR 1.4 to 2.8. Patients were randomized to active aspirin
or warfarin and an identical placebo. No patients received
two placebo or two active treatments.
TEE protocol and analysis. All patients underwent TEE
guided by a predefined protocol using either a biplane or
multiplane TEE probe and the videotapes were sent to
Columbia for central analysis. The TEE protocol empha-
sized extensive characterization of interatrial septum and
RA anatomy. Saline contrast injection with and without
Valsalva maneuver or cough was performed for PFO detec-
tion. Ongoing quality control was monitored with feedback
to the site regarding TEE study quality.
All TEE tapes were analyzed by a single observer (S. H.).
All measurements were made blinded to treatment assign-
ment, stroke subtype, or outcome. The PFO was deter-
mined to be present if, upon saline contrast injection, there
was appearance of at least one microbubble in the left atrium
within three cardiac cycles following opacification of the
right atrium (26,27). The PFO was distinguished from
atrial septal defect by the presence of overlap of septum
primum and secundum. The number of microbubbles was
counted from an image demonstrating the maximum num-
ber on a video frame within three cardiac cycles from the
opacification of right atrium (7,28). Measurements were
made from resting contrast injection and in conjunction
with Valsalva maneuver or cough, whichever demonstrated
a larger PFO size or shunt. Each PFO was determined to be
large or small, as previously described (17).
The SA was defined as a motion of atrial septum into left
or right atrium of at least 10 mm from its midline position
(29). Prominent EV was defined as a protrusion into the
right atrium of 10 mm or more of linear membrane-like
structure from the junction of right atrium with IVC in the
image plane demonstrating the entrance of IVC into right
atrium in a vertical plane using biplane probe, or an
equivalent plane using multiplane probe. Right atrial fila-
mentous strands were defined as freely mobile linear fila-
mentous structures in RA with attachment to EV or to any
aspect of RA wall. Inter- and intra-observer variability for
determination of the presence of prominent EV or RA
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filamentous strands was performed by blinded interpretation
of 15 studies.
Follow-up. All patients were followed for two years, op-
erationalized as 24  1 month (maximum 761 days).
Follow-up was made on a monthly basis by phone or
in-person to assess compliance and to regulate INRs.
Quarterly and annual in-person follow-ups for detailed
examination were also made.
Assessment of end points. The primary end point was
recurrent ischemic stroke or death from any cause. Tran-
sient ischemic attack (TIA) was included for secondary end
points. Clinical evidence of a recurrent ischemic stroke was
a new lesion on computed tomography or magnetic reso-
nance image, or when new lesions were absent, clinical
syndrome consistent with stroke of 24 h duration. All
clinical and radiological events were adjudicated indepen-
dently by a panel blinded to treatment assignment.
Statistical analysis. The significance of differences in so-
ciodemographic variables, stroke characteristics, and stroke
risk factors was assessed by unpaired t test for continuous
variables and by Fisher exact test for categorical variables.
Kaplan-Meier curves were constructed and a Cox propor-
tional hazards model was used to determine the relative
hazard ratio and associated 95% confidence interval (CI) for
subjects with SA and PFO compared with subjects with
neither SA nor PFO. Similar analyses were performed
comparing subjects with the combination of SA, PFO, and
prominent EV or RA filamentous strands with subjects
having none of these findings. These analyses were per-
formed for the group as a whole, and in the cryptogenic
stroke patients. In subjects with SA and PFO, warfarin was
compared with aspirin. Reported event rates at two years
were derived from the Kaplan-Meier curves, which adjusted
for censoring. A value p  0.05 was considered significant
for all analyses.
RESULTS
The PICSS enrolled 630 (28.6%) of 2,206 WARSS pa-
tients. When the strokes of 630 PICSS patients were
subtyped, 265 (42.1%) were cryptogenic, 244 (38.7%) were
lacunar, 68 (10.8%) were large vessel, 27 (4.3%) were other
determined cause, and 26 (4.1%) were conflicting mecha-
nisms. The mean INR in the warfarin-treated group was
2.04  0.99.
Baseline TEE findings. Of 630 patients, TEE studies
were available for analysis in 627 patients. Of these, 601
(95.9%) patients had TEE images adequate for analysis of
PFO, 600 (95.7%) for analysis of SA, 563 (89.8%) for
analysis of EV, and 563 (89.8%) for analysis of RA
filamentous strands. Lower adequacy for determination of
EV or RA filamentous strands derived from the stringent
criteria used to determine its presence. The PFO was
present in 203 (33.8%) of the patients, of which 58.6%
(119/203) were classified as small and 41.4% (84/203) as
large. Atrial septal aneurysm was present in 11.5% (69/600),
prominent EV was seen in 34.6% (195/563), and RA
filamentous strands was present in 18.8% (106/563). A
combination of SA and PFO was found in 7.3% (44/600).
Right atrial anatomical variation favoring IVC flow towards
the fossa ovalis area, a prominent eustachian valve or RA
filamentous strands was found in 44.9% (252/561). Blinded
interpretation of the studies for determination of the pres-
ence of prominent EV or RA filamentous strands showed
complete agreement, both within and between observers.
Relationship of SA with PFO, prominent EV, or RA
filamentous strands. As shown in Table 1, SA was
strongly associated with the presence of PFO, and these
PFOs were larger than those found without SA. Atrial
septal aneurysm was associated with the presence of prom-
inent EV or RA filamentous strands, and the combination
of a large PFO and prominent EV or RA filamentous
strands was strongly associated with the presence of SA.
When a more stringent criteria of three or microbubbles for
the presence of PFO, and 20 or more microbubbles for large
PFO was applied, the findings did not change. Further-
more, when the patients were divided into those 50 years
of age and those 50 years of age, in both groups, SA was
associated with the presence of PFO and large PFO.
End points. The analyses were adjusted for the 10 patients
lost to follow-up using a prespecified imputation procedure
(22). Using this model, the overall primary event rate was
15.9%. Among the 600 patients with TEE images adequate
for analysis of SA and PFO, there were a total of 92 end
points (15.3%). Seventy-one strokes and 21 deaths occurred.
Additionally, 34 TIAs occurred, including seven that oc-
curred before the primary event. The rate of major hemor-
rhage was similar between the patients on warfarin and
those on aspirin, but the rate of minor hemorrhage was
significantly higher in patients on warfarin compared with
those on aspirin (17).
Efficacy of medical therapy. In the overall patient popu-
lation the event rate in patients with SA and PFO was
compared with that in patients with neither SA nor PFO.
Demographics, stroke characteristics, and risk factors were
similar between these groups (Table 2). Criteria for clinical
variables have been previously defined (22). In the overall
Table 1. PFO Characteristics and Prominent EV or RA
Filamentous Strands in Patients With and Without SA
SA Present
(N  69)
SA Absent
(N  532) p Value
PFO 63.8% (44/69) 29.9% (159/531)  0.001
Large PFO 37.7% (26/69) 10.9% (58/531)  0.001
Prominent EV or RA
filamentous strands
59.4% (38/64) 43.1% (214/497) 0.02
Large PFO and
prominent EV or
RA filamentous
strands
21.9% (14/64) 5.0% (25/497)  0.001
EV  eustachian valve; PFO  patent foramen ovale; RA  right atrial; SA  atrial
septal aneurysm.
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group, there was no significant difference in time to recur-
rent stroke or death in those with SA and PFO compared
with the patients with neither of these findings (Table 3).
With the addition of TIA as an additional end point, there
also was no significant difference. When the cryptogenic
subtype was considered separately, there were no significant
differences in the time to end point with and without
inclusion of TIA (Table 3). We then compared the patients
with SA and PFO, along with prominent EV or RA
filamentous strands with those without any of these find-
ings. Demographic and stroke characteristics and risk fac-
tors were similar between the comparison groups (Table 4).
In the overall as well as in the cryptogenic subset, there was
no difference in the time to end points between the groups
with and without TIA as an additional end point (Table 5).
When the efficacy of warfarin and aspirin was compared in
the patients with SA and PFO, there was no significant
difference in the time to recurrent stroke or death between
the two treatment arms. This was also the case when TIA
was included as an additional end point (Table 6). When a
more stringent criterion of three or more microbubbles was
used to define PFO, no significant changes were noted in
any of the outcome findings.
DISCUSSION
There are very few studies that have assessed whether the
presence of SA and PFO or SA and PFO along with
prominent EV or RA filamentous strands increases adverse
event rates compared to patients without these findings.
There are a variety of percutaneous devices that may be used
for closing PFO in patients with SA, a perceived high-risk
group (18,19). Before the efficacy of these modalities can be
defined, the risk of recurrent stroke or death in medically
treated patients needs to be defined.
We found that PFO was frequently found in the presence
of SA, as was previously noted (30,31). We also found that
large PFOs are frequently found in the presence of SA with
an increased potential for paradoxical embolization. In the
past studies, large PFO has been associated with crypto-
genic stroke (7,8). Thus, the higher stroke risk in patients
with SA and PFO may in part derive from the frequent
presence of large PFO in patients with SA and PFO.
Furthermore, we found that SA is associated with the
presence of prominent EV or RA filamentous strands, both
remnants of right valve of sinus venosus (12,13). In adult
life, EV has been associated with cyanosis in patients with
atrial septal defect presumably by diverting IVC flow into
Table 2. Demographic and Stroke Characteristics of Patients With SA and PFO Compared
With Neither SA Nor PFO
Variable
SA/PFO
(N  44)
No SA/No PFO
(N  372) p Value*
Sociodemographic
Age 58.7  13.7 59.3  11.7 0.77
Male gender 23/44 (52.3%) 205/372 (55.1%) 0.75
Stroke characteristics
Cryptogenic subtype 22/44 (50.0%) 143/372 (38.4%) 0.15
Glasgow score 5 13/44 (29.6%) 131/372 (35.2%) 0.51
Barthel score 95 12/44 (27.3%) 105/372 (28.2%) 1.0
Risk factors
Hypertension 23/44 (52.3%) 231/365 (63.3%) 0.19
Diabetes 8/43 (18.6%) 121/371 (32.6%) 0.08
Heart disease 7/44 (15.9%) 64/372 (17.2%) 1.0
Prior stroke 8/42 (19.1%) 50/342 (14.6%) 0.49
Current smoker 7/44 (15.9%) 114/370 (30.8%) 0.05
Sedentary 13/42 (31.0%) 140/369 (37.9%) 0.41
Obese 24/44 (54.6%) 178/372 (47.9%) 0.43
Heavy alcohol consumption 3/44 (6.8%) 46/370 (12.4%) 0.46
Moderate alcohol consumption 20/44 (45.5%) 142/370 (38.4%) 0.42
*PFO with SA vs. no PFO or SA.
Abbreviations as in Table 1.
Table 3. Two-Year Event Rates in Patients With SA and PFO Compared With Patients
Without SA or PFO
SA/PFO No SA/No PFO HR (95% CI) p Value
Overall group N  44 N  372
Death or stroke 15.9% 14.5% 1.08 (0.49–2.38) 0.84
Death, stroke, or TIA 18.2% 18.6% 0.95 (0.46–1.98) 0.90
Cryptogenic N  22 N  143
Death or stroke 18.2% 12.1% 1.63 (0.55–4.84) 0.38
Death, stroke, or TIA 18.2% 16.3% 1.18 (0.41–3.40) 0.76
CI  confidence interval; HR  hazard ratio; TIA  transient ischemic attack. Other abbreviations as in Table 1.
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the left atrium (10,11). Chiari network, an extensive net-
work of RA filamentous strands, has been associated with
paradoxical embolization, likely by directing embolic mate-
rial from IVC into the fossa ovalis (15). We believe these
anatomical features in part account for the combination of
SA and PFO being strongly associated with stroke.
This study is the first to define the relationship between
SA with large PFO and EV or RA filamentous strands.
This study is also the first to assess the efficacy of medical
therapy in double-blind–treated patients with SA and PFO,
as well as in patients with SA, PFO, and RA anatomy
favoring paradoxical embolization. The PICSS offered a
unique opportunity to assess the adverse event rates in a
carefully screened cohort of stroke patients (17). Patients
were double-blindly assigned to warfarin or aspirin, and
follow-up was conducted using uniform criteria with a very
small number of patients lost to follow-up. All TEE studies
were centrally and blindly analyzed using uniform criteria.
We have previously reported that on medical therapy the
presence of SA in stroke patients with PFO does not
increase the adverse event rate beyond that seen with PFO
alone (17). In this study, we further demonstrate that
patients with SA and PFO have similar event rates even
when compared with those with neither SA nor PFO.
Moreover, the presence of EV or RA filamentous strands in
patients with PFO and SA did not increase the adverse
event rates compared with the patients without any of these
findings. Thus while on medical therapy, patients with PFO
and SA, as a whole, do not experience increased event rate
compared with those without such findings. This implies
that either the medical therapy is effective or that the
presence of PFO and SA confers a degree of risk not
detected by our study.
When warfarin was compared with aspirin in patients
with PFO and SA, there was no difference in the adverse
event rates between the treatment arms. The mean INR of
the warfarin-treated patients in PICSS was 2.04 (17). In
WARSS, an INR 1.5 proved to be effective in reducing
adverse events (22). Thus, we believe adequate INR was
achieved in our population. Prior to events, in patients
Table 4. Demographic and Stroke Characteristics of Patients With SA, PFO, and EV or RA
Filamentous Strands Compared With Patients With No PFO, SA, EV, or RA Filamentous Strands
Variable
SA/PFO With
EV or RA
Filamentous
Strands
No SA, PFO
EV or RA
Filamentous
Strands
p Value*(N  22) (N  197)
Sociodemographic
Age 59.6  11.9 58.6  11.6 0.69
Male gender 13/22 (59.1%) 115/197 (58.4%) 1.0
Stroke characteristics
Cryptogenic subtype 10/22 (45.5%) 73/197 (37.1%) 0.49
Glasgow score 5 7/22 (31.8%) 67/197 (34.0%) 1.0
Barthel score 95 3/22 (13.6%) 45/197 (22.8%) 0.42
Risk factors
Hypertension 13/22 (59.1%) 120/192 (62.5%) 0.82
Diabetes 5/21 (23.8%) 70/197 (35.5%) 0.34
Heart disease 4/22 (18.2%) 34/197 (17.3%) 1.0
Prior stroke 6/20 (30.0%) 31/180 (17.2%) 0.22
Current smoker 2/22 (9.1%) 57/197 (28.9%) 0.07
Sedentary 7/20 (35.0%) 68/196 (34.7%) 1.0
Obese 13/22 (59.1%) 81/197 (41.1%) 0.12
Heavy alcohol consumption 1/22 (4.6%) 23/197 (11.7%) 0.48
Moderate alcohol consumption 11/22 (50.0%) 78/197 (39.6%) 0.37
*p value  SA and PFO with EV or RA filamentous strands vs. no SA, PFO, EV, or RA filamentous strands.
Abbreviations as in Table 1.
Table 5. Two-Year Event Rates in Patients With SA and PFO With EV or RA Filamentous
Strands Compared With Patients Without SA, PFO, EV, or RA Filamentous Strands
SA/PFO With
EV, or RA
Filamentous
Strands
No SA, PFO,
EV, or RA
Filamentous
Strands HR (95% CI) p Value
Overall group N  22 N  197
Death or stroke 18.2% 14.2% 1.22 (0.43–3.47) 0.71
Death, stroke, or TIA 18.2% 17.3% 0.98 (0.35–2.76) 0.97
Cryptogenic N  10 N  73
Death or stroke 10.0% 11.0% 0.85 (0.11–6.81) 0.88
Death, stroke, or TIA 10.0% 13.7% 0.67 (0.09–5.23) 0.70
Abbreviations as in Tables 1 and 3.
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experiencing events, the INR was 1.8  1.0. Although the
range of INR was wide, this was not significantly different
from the level in those without events. Although the choice
of medical therapy did not make a difference, its efficacy will
depend on how accurately we can attribute the ischemic
event to paradoxical embolization. Indeed, in those with
deep venous thrombosis, warfarin is likely to be more
effective compared with aspirin in preventing recurrent
neurological events in patients with PFO and SA.
In comparing our study with a recent study reporting
high adverse event rates in the patients with SA and PFO,
our patients were significantly older (16). Adverse event
rates and the efficacy of medical therapy for stroke patients
with PFO may very well differ according to the age of the
subjects. Also, if the follow-up period was significantly
longer, differences may have been detected. However, given
the similarity in event rates, a considerably longer period
would have been necessary.
Conclusions. We show that large PFO and RA anatomy
favoring paradoxical embolization are associated with the
presence of SA, providing a plausible mechanism for the
strong association of the combination of SA and PFO with
stroke. We also demonstrate similar outcome rates in these
patients compared with those with neither PFO nor SA
while on medical therapy consisting of warfarin or aspirin.
Event rates were similar even when the RA structures
favoring paradoxical embolization were present. This ap-
plied to both the study population as a whole and the
cryptogenic stroke patients. Furthermore, when warfarin
was compared with aspirin in patients with SA and PFO, no
significant differences were noted. It remains to be seen if
other therapeutic modalities, such as percutaneous PFO
closure, reduces the event rate in these patients.
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APPENDIX
For a complete list of the PICSS study participants as well
as a list of the number of patients that contributed to the
PICSS and the names of the institutions, local neurology
principal investigators, cardiology investigators, and coordi-
nators, please see the September 17, 2003, issue of JACC at
www.cardiosource.com/jacc.html.
1072 Homma et al. JACC Vol. 42, No. 6, 2003
Atrial Anatomy and Stroke September 17, 2003:1066–72
